Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of membranous nephropathy comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Simponi, and UCB’s Cimzia) are approved to treat nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe and are…
Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
The negative symptoms of schizophrenia, which often coexist with the positive symptoms, include diminished emotional expression (affective flattening), diminished initiation of goal-directed…
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…